It is better to be in a clinical trial than not: lessons learnt from clinical neurology—the management of acute multiple sclerosis relapses

QJM: An International Journal of Medicine, 05/03/2012

The effect observed is likely secondary to trial participation; both groups had similar baseline features, and were treated in the same way. Likely mechanisms for the differences are protocol, care and Hawthorne effects. The findings support the incorporation of structured randomized controlled trial (RCT)–style practice into routine clinical management, in order to deliver a more patient–centred care in the treatment of multiple sclerosis relapses. This may have implications for other chronic neurological diseases.

Print Article Summary Cat 2 CME Report